LH, FSH, TSH, prolactin, HCG and prostaglandin F2 alpha in patients with treated testis tumors.
Various kinds of treatments of testicular cancer results in significant changes in peptide hormones, particularly LH and FSH. In some cases, compensated hypothyroidism as indicated by increased TSH with normal T3 are observed. Serum levels of prostaglandin F2 alpha are also elevated after therapy without relation to the stage of the disease. During followup, these patients are found to complain of impotence and infertility, and the evaluation of serum analysis of peptide hormones must consider both the normal hormonal findings of treated testicular cancer patients and recurrence of endocrine active tumor. The hormonal changes from hypophyseal origin are secondary to the primary testicular damages in patients complaining of impotence without tumor recurrence.
D006063:Chorionic Gonadotropin / Q000097:blood*; D004407:Dysgerminoma / Q000097:blood; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D010908:Pituitary Hormones, Anterior / Q000097:blood*; D011388:Prolactin / Q000097:blood; D011460:Prostaglandins F / Q000097:blood*; D013724:Teratoma / Q000097:blood; D013736:Testicular Neoplasms / Q000097:blood / Q000628:therapy*; D013972:Thyrotropin / Q000097:blood
D006063:Chorionic Gonadotropin; D010908:Pituitary Hormones, Anterior; D011460:Prostaglandins F; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin